» Articles » PMID: 33925992

Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis

Abstract

Background: Fatty liver index (FLI) is a non-invasive tool used to stratify the risk of non-alcoholic fatty liver disease (NAFLD) in population studies; whether it can be used to exclude or diagnose this disorder is unclear. We conducted a meta-analysis to assess the prevalence of NAFLD in each FLI class and the performance of FLI in detecting NAFLD.

Methods: Four databases were searched until January 2021 (CRD42021231367). Original articles included were those reporting the performance of FLI and adopting ultrasound, computed tomography, or magnetic resonance as a reference standard. The numbers of subjects with NAFLD in FLI classes <30, 30-60, and ≥60, and the numbers of subjects classified as true/false positive/negative when adopting 30 and 60 as cut-offs were extracted. A random-effects model was used for pooling data.

Results: Ten studies were included, evaluating 27,221 subjects without secondary causes of fatty liver disease. The prevalence of NAFLD in the three FLI classes was 14%, 42%, and 67%. Sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio for positive results, likelihood ratio for negative results, and diagnostic odds ratio were 81%, 65%, 53%, 84%, 2.3, 0.3, and 7.8 for the lower cut-off and 44%, 90%, 67%, 76%, 4.3, 0.6, and 7.3 for the higher cut-off, respectively. A similar performance was generally found in studies adopting ultrasound versus other imaging modalities.

Conclusions: FLI showed an adequate performance in stratifying the risk of NAFLD. However, it showed only weak evidence of a discriminatory performance in excluding or diagnosing this disorder.

Citing Articles

Impact of non-alcoholic fatty liver disease and liver fibrosis on outcomes of acute ischemic stroke: A systematic review and meta-analysis.

Yang L, Han J, Qin C, Song F Pak J Med Sci. 2025; 41(2):630-636.

PMID: 39926662 PMC: 11803813. DOI: 10.12669/pjms.41.2.10729.


Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK Biobank.

Qiao Y, Wang Y, Chen C, Huang Y, Zhao C Cardiovasc Diabetol. 2025; 24(1):12.

PMID: 39806394 PMC: 11730479. DOI: 10.1186/s12933-024-02572-w.


Impact of Dietary Niacin on Metabolic Dysfunction-Associated Steatotic Liver Disease in Mediterranean Subjects: A Population-Based Study.

Antentas M, Rojo-Lopez M, Vendrell P, Granado-Casas M, Genua I, Fernandez-Camins B Nutrients. 2024; 16(23).

PMID: 39683571 PMC: 11644089. DOI: 10.3390/nu16234178.


[Serum indices of hepatic steatosis in indigenous Venezuelan adults of the Piaroa ethnic group].

Nobrega D, Diaz-Castro M, Freites-Portocarrero A, Fuentes-Bielinis L, Gaize-Garcia B, Luna-Sanchez V Rev Fac Cien Med Univ Nac Cordoba. 2024; 81(4):686-704.

PMID: 39670903 PMC: 11905789. DOI: 10.31053/1853.0605.v81.n4.44477.


Metabolic dysfunction-associated steatotic liver disease: The question of long-term high-normal alanine aminotransferase as a screening test.

Moyana T World J Gastroenterol. 2024; 30(42):4576-4582.

PMID: 39563746 PMC: 11572615. DOI: 10.3748/wjg.v30.i42.4576.


References
1.
Younossi Z, Stepanova M, Ong J, Jacobson I, Bugianesi E, Duseja A . Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol. 2018; 17(4):748-755.e3. DOI: 10.1016/j.cgh.2018.05.057. View

2.
Chen L, Huang P, Chien C, Lin C, Chien R . A community-based study on the application of fatty liver index in screening subjects with nonalcoholic fatty liver disease. J Formos Med Assoc. 2019; 119(1 Pt 1):173-181. DOI: 10.1016/j.jfma.2019.03.016. View

3.
Koehler E, Schouten J, Hansen B, Hofman A, Stricker B, Janssen H . External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013; 11(9):1201-4. DOI: 10.1016/j.cgh.2012.12.031. View

4.
Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

5.
Huh J, Kim J, Choi E, Kim J, Chang Y, Sung K . The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. PLoS One. 2017; 12(7):e0180951. PMC: 5524328. DOI: 10.1371/journal.pone.0180951. View